

Nonconfidential Summary Disclosure



UM 3920: Lidocaine Hydrochloride & Triamcinolone Acetonide for Topical Use

THE TECHNOLOGY

This technology features a proprietary formulation that stabilizes the combination of lidocaine hydrochloride and triamcinolone acetonide in a bioadhesive base allowing for targeted and immediate pain relief for various indications. Topically applied prescription and over-the-counter drug products containing either lidocaine hydrochloride or triamcinolone acetonide are commonly used for a variety of skin and mucosal membrane conditions such as rashes, burns, insect bites, aphthous ulcers and hemorrhoids.

Lidocaine hydrochloride is a local anesthetic that reduces conduction of nerve impulses resulting in temporary numbness/loss of feeling in the skin and mucous membranes. Drug products containing 2 to 5% by weight lidocaine hydrochloride are used for relief of itching and pain on the skin, rectum and oral cavity.

Triamcinolone acetonide is a topically applied corticosteroid that has anti-inflammatory, anti-pruritic and vasoconstrictive actions. Drug products containing 0.025% to 0.5% by weight of triamcinolone acetonide are used to treat inflammation on the skin, rectum and oral cavity caused by a number of conditions such as allergic reactions, eczema, and hemorrhoids.

Two U.S. based Phase II clinical studies have been completed using patients suffering from aphthous ulcers as a model condition. The results of the clinical studies demonstrated rapid and prolonged relief of pain with significant reduction in the duration of an episode.

COMPETITIVE ADVANTAGE

This technology overcomes the drawbacks of traditional topical formulations (e.g. creams, gels and ointments) comprising a combination of lidocaine and triamcinolone that are chemically unstable and suffer from a very short shelf life.

There is a need for topical formulations that combine the therapeutic properties of a local anesthetic and a steroidal anti-inflammatory to provide immediate and localized pain relief and reduced healing times.

DEVELOPMENT POTENTIAL

The University is seeking a commercial partner to complete the required regulatory studies. The technology is available for different indications.

PATENT STATUS

USA: 9,801,837 and 10,335,381 (CON)
Also issued in Canada, India, Germany, Spain, United Kingdom, Netherlands, and Sweden

PRINCIPAL INVESTIGATOR(S)

Dr. Michael A. Repka, Professor and Chair of
Pharmaceutics and Drug Delivery

KEYWORDS

Lidocaine, Triamcinolone, Topical Steroid, Topical Anesthetic, Bioadhesive



ALLYSON BEST

Director of Technology Commercialization
The University of Mississippi
University, MS 38677
662.915.7188
amilhous@olemiss.edu



OFFICE of TECHNOLOGY
COMMERCIALIZATION
UNIVERSITY of MISSISSIPPI